On the Horizon – Denosumab, An alternative To Zometa To Protect Bones While Treating Advanced Prostate Cancer

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]

Dealing with the Worry of Developing a Met

Every time I feel any pain, especially when it is in my chest or lower back, the little birdie whispers to me that I have finally developed a bone met. What are just the normal aches and pains from getting older sometimes seem to magnify and turn on the worry switch. It isn’t dissimilar to [...]

Using Gold Markers with Focused Radiation to Treat Adrenal Mets

Men with advanced prostate cancer who develop an adrenal tumor will usually undergo laparoscopic adrenalectomy (removal of the adrenal gland) as a treatment method. Just like with prostate surgery. in some situations surgery might not be the best alternative for an individual man. An individual case was recently completed at the Department of Renal and [...]

X-rays Help Predict Permanent Bone Damage From Bisphosphonates

Taking bisphosphonates as a part of our prostate cancer treatment puts all of us in direct risk of developing osteoporosis. Bisphosphonates have been found to place us in a high-risk state for developing osteonecrosis of the jaws (rotting of the jaw bones). It is now possible to use X-rays to detect "ghost sockets" in the [...]

A First Generation Bisphosphnate Increases Overall Survival in Metastatic Prostate Cancer

A recent report from England, about the first-generation oral bisphosphonate sodium clodronate, claims to improve overall survival in men with metastatic but not localized prostate cancer, according to long-term data from two randomized controlled trials. Among the sample of 278 men all who had metastatic disease starting and who were responding to long-term hormone therapy, [...]

Go to Top